Department of Gastroenterological Surgery, Hyogo Cancer Center, 13-70, Kitaoji-cho, Akashi City, Hyogo, 673-8558, Japan.
Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Hyogo, Japan.
Langenbecks Arch Surg. 2019 Sep;404(6):753-760. doi: 10.1007/s00423-019-01821-x. Epub 2019 Sep 4.
Completion gastrectomy (CG) is a common procedure for remnant gastric cancer (RGC). However, partial gastrectomy for gastric cancer has several benefits compared to total gastrectomy in terms of the quality of life. In this study, we evaluated the feasibility and advantage of subtotal resection of the remnant stomach (SR) for clinical stage IA RGC.
A total of 43 patients who underwent gastrectomy for clinical stage IA RGC were included. CG and SR were performed on 27 (62.8%) and 16 patients (37.2%), respectively. The short- and long-term outcomes, including the nutritional status, after CG and SR for clinical stage IA RGC were compared between the two groups.
There were no significant differences in pathological stage or incidence of postoperative complications between the two groups. The decrease in body weight, body mass index, and serum albumin level was significantly lower in the SR group than in the CG group (P < 0.001, P = 0.025, and 0.008). In the SR group, there was no recurrence at the remaining lymph nodes or gastric stump. The 5-year overall survival rate was 87.8% in the CG group and 86.1% in the SR group, without a significant difference between the two groups (P = 0.959).
The present study showed the noninferiority of SR to CG based on surgical and oncological outcomes for clinical stage IA RGC. Furthermore, SR has an advantage over CG in terms of postoperative nutritional status. Therefore, SR could be an alternative elective treatment option for early RGC located around the anastomotic site.
残胃癌(RGC)的常用治疗方法是完成性胃切除术(CG)。然而,与全胃切除术相比,胃癌部分切除术在生活质量方面具有若干优势。在本研究中,我们评估了次全胃切除术(SR)治疗临床 I 期 RGC 的可行性和优势。
共纳入 43 例接受胃切除术治疗临床 I 期 RGC 的患者。27 例(62.8%)患者行 CG,16 例(37.2%)患者行 SR。比较两组患者 CG 和 SR 治疗临床 I 期 RGC 的短期和长期结果,包括营养状况。
两组患者的病理分期或术后并发症发生率无显著差异。与 CG 组相比,SR 组患者的体重、体重指数和血清白蛋白水平下降幅度明显较低(P<0.001、P=0.025 和 0.008)。在 SR 组,未在残留淋巴结或残胃发生复发。CG 组和 SR 组的 5 年总生存率分别为 87.8%和 86.1%,两组间无显著差异(P=0.959)。
本研究基于手术和肿瘤学结果显示,SR 治疗临床 I 期 RGC 不劣于 CG。此外,SR 在术后营养状况方面优于 CG。因此,SR 可能是位于吻合部位附近的早期 RGC 的另一种选择性治疗方法。